2014 Archived Content
With the aging of the population, the need for treatments of ocular diseases and disorders has become more important than ever. Increasingly high incidences of age-related macular degeneration (AMD), glaucoma, diabetic retinopathy and ocular inflammatory diseases demand better, more effective and innovative treatments. If we are to maintain the quality of life for this aging population, the preservation of vision is critical. This conference will address targeting of ophthalmic medications and treatments and will provide the latest results in the field, along with novel and emerging targets that hold promise in treating these quality of life threats.
Topics Include:
- New disease pathways
- Alternative drugs
- Anti-inflammatories
- Biologics
- Bi-specific therapies
- Novel therapeutics
- Anti-angiogenics
- Drugs in clinical trials
FEATURED PRESENTATION
Systemic Administration of Anti-Ab mAb Reduces Retinal Deposition of Abeta and Activated Complement C3 in Age-Related Macular Degeneration Mouse Model
Ian R. Catchpole, Ph.D., Topical BioPharm Discovery Research and Development, Glaxo-Smith Kline